Stethoscope
© Jesper Dudal

New project to treat psoriasis

Project E!7783 PAT (Psoriasis Anti-inflammatory Treatment), an initiative designed to find a treatment of the immune-mediated disease psoriasis, has been approved as a part of Eurostars, a joint programme between EUREKA and the European Union specifically dedicated to innovative SMEs.

The project will focus on acquiring the knowledge needed to proceed on to preclinical studies and eventually trials for oral and topical treatment based on their TMX-302 concept.

Dr Johanna Holldack, CEO at Telormedix, said: “We are absolutely delighted to have secured this funding with such a world class consortium to bring TMX-302 to preclinical proof of concept.”

The project consortium consists of three countries (Spain, Switzerland and the United Kingdom) and five companies (Telormedix and the University Hospital Zurich’s Department of Dermatology (Switzerland), Midatech Biogune SL (Spain), and Biopta Ltd and Molecular Profiles Ltd (UK).

The project will last just under two years and was awarded €1.77m. Psoriasis affects the skin and upwards of 125 million people worldwide. In Europe alone, the disease affects nearly 5 million people.